Q-omics provides the consensus-scored PBDC1 profile across patient tissues and cancer cell-line models. PBDC1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PBDC1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, PBDC1 protein abundance shows 32,335 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, and GBM as cancer lineages where PBDC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PBDC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PBDC1 survival associations across molecular data types. PBDC1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PBDC1 RNA expression–survival associations across cancer types. High PBDC1 expression shows unfavorable associations in HNSC, UVM, ACC, LUAD and UCS, but favorable associations in THCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PBDC1 RNA expression.
This table summarizes PBDC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PBDC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PBDC1 shows lower tumor expression in KIRC and higher tumor expression in HNSC, LIHC, READ, COAD and STAD. The HNSC box plot shows higher PBDC1 RNA expression in tumor versus normal tissue (log2 FC = +0.706, t-test p < 0.001).
This table shows molecular features associated with PBDC1 in patient tissues and cancer cell lines. In patient samples, PBDC1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PBDC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
